Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 591.5 g/mol |
|---|---|
| Molecular Formula | C12H17NO20S3-4 |
| XLogP3 | -5.6 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 21 |
| Rotatable Bond Count | 6 |
| Exact Mass | 590.95060545 g/mol |
| Monoisotopic Mass | 590.95060545 g/mol |
| Topological Polar Surface Area | 376 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | -4 |
| Complexity | 1040 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 6 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Heparin sodium in plastic container |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 2 of 4 | |
|---|---|
| Drug Name | Heparin sodium preservative free |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Hospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Heparin sodium in plastic container |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 4 of 4 | |
|---|---|
| Drug Name | Heparin sodium preservative free |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Hospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms |
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9939
Submission : 1992-11-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31703
Submission : 2017-04-21
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25556
Submission : 2011-12-20
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2018-02-22
Pay. Date : 2014-07-25
DMF Number : 20541
Submission : 2007-03-27
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29154
Submission : 2015-03-06
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10596
Submission : 1993-12-07
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20905
Submission : 2007-09-25
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21950
Submission : 2008-09-01
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19038
Submission : 2005-12-15
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19658
Submission : 2006-08-04
Status : Inactive
Type : II
Registration Number : 227MF10152
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigine (Modena) Italy
Initial Date of Registration : 2015-06-01
Latest Date of Registration :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9939
Submission : 1992-11-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21950
Submission : 2008-09-01
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-02-22
Pay. Date : 2014-07-25
DMF Number : 20541
Submission : 2007-03-27
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20905
Submission : 2007-09-25
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25556
Submission : 2011-12-20
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29154
Submission : 2015-03-06
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10596
Submission : 1993-12-07
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19658
Submission : 2006-08-04
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19038
Submission : 2005-12-15
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31703
Submission : 2017-04-21
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registration Number : 223MF10084
Registrant's Address : No. 18 Guoxiang Road, Wujin Economic Development Zone, Changzhou City, Jiangsu Provin...
Initial Date of Registration : 2011-06-17
Latest Date of Registration : 2019-01-10

Registration Number : 301MF10042
Registrant's Address : No. 18 Guoxiang Road, Wujin Economic Development Zone, Changzhou City, Jiangsu Provin...
Initial Date of Registration : 2019-08-09
Latest Date of Registration : 2019-08-09

Registration Number : 218MF10583
Registrant's Address : No. 1, Changhong West Road, Hutang Town, Wujin District, Changzhou City, Jiangsu Prov...
Initial Date of Registration : 2006-06-22
Latest Date of Registration : 2009-12-25

Registration Number : 219MF10099
Registrant's Address : No. 192 Huanghe West Rd. Xinbei District Changzhou, Jiangsu, China
Initial Date of Registration : 2007-03-14
Latest Date of Registration : 2014-05-21

Registration Number : 227MF10152
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigine (Modena) Italy
Initial Date of Registration : 2015-06-01
Latest Date of Registration : 2015-06-01

Registration Number : 308MF10011
Registrant's Address : No. 71, Menglong Street, South District of Zhengding High-tech Industrial Development...
Initial Date of Registration : 2026-01-08
Latest Date of Registration : 2026-01-08

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Registration Number : 221MF10099
Registrant's Address : Nanjing High-tech Development Zone MA010-1
Initial Date of Registration : 2009-05-27
Latest Date of Registration : 2022-07-06

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Ilsung IS Co., Ltd.
Registration Date : 2025-02-21
Registration Number : 20250221-211-J-1761
Manufacturer Name : ROVI ESCÚZAR, SL
Manufacturer Address : Avenida de la Serrezuela, 5518130 ESCÚZAR (GRANADA), SPAIN

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Biological E Limited, established in 1953 is globally focused one of the largest manufacturer of Human Vaccines, currently manufacturing Tetanus, DT, DTP, Td, Hepatitis B, DTP-HepB...

About the Company : Dongying Tiandong Pharmaceutical Co.,ltd founded in 1992, subordinated to Shandong Haike Chemical Group, is located in Dongying city, the center area of Yellow River Delta High-eff...

About the Company : A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju, who has always thought far ahead of his...

About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...

About the Company : Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and Manufacturing APIs and Advanced Intermediates for Active Pharmaceutical Ing...

About the Company : Yangzhou Pharmaceutical Co., Ltd is one of the middle-scale state-owned comprehensive enterprises. It has fixed assets of RMB 22 million and covers land of area of 120 000m2. It em...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 23, 2022

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2022

Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Leo Pharma | Sunnybrook Research Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2021

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Leo Pharma | Sunnybrook Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2021

Details:
Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Innohep
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2015

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Product Name : Innohep
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2015

Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2014

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Christine Ribic
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Christine Ribic
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Tinzaparin for Anticoagulation in Hemodialysis
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Details : Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Nephrology Brand Name: Fragmin
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use Of Fragmin In Hemodialysis
Details : Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Fragmin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2013

Details:
Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Lead Product(s): Dalteparin sodium,Enoxaparin Sodium,Tedelparin
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 11, 2013

Lead Product(s) : Dalteparin sodium,Enoxaparin Sodium,Tedelparin
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2013

Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Aarhus University Hospital | Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2011

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Aarhus University Hospital | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Innohep
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Veno...
Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.
Product Name : Innohep
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
38
PharmaCompass offers a list of Dalteparin sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dalteparin sodium manufacturer or Dalteparin sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dalteparin sodium manufacturer or Dalteparin sodium supplier.
PharmaCompass also assists you with knowing the Dalteparin sodium API Price utilized in the formulation of products. Dalteparin sodium API Price is not always fixed or binding as the Dalteparin sodium Price is obtained through a variety of data sources. The Dalteparin sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Heparin sodium 25,000 units and dextrose 5% in plastic container manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Heparin sodium 25,000 units and dextrose 5% in plastic container, including repackagers and relabelers. The FDA regulates Heparin sodium 25,000 units and dextrose 5% in plastic container manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Heparin sodium 25,000 units and dextrose 5% in plastic container API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Heparin sodium 25,000 units and dextrose 5% in plastic container manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Heparin sodium 25,000 units and dextrose 5% in plastic container supplier is an individual or a company that provides Heparin sodium 25,000 units and dextrose 5% in plastic container active pharmaceutical ingredient (API) or Heparin sodium 25,000 units and dextrose 5% in plastic container finished formulations upon request. The Heparin sodium 25,000 units and dextrose 5% in plastic container suppliers may include Heparin sodium 25,000 units and dextrose 5% in plastic container API manufacturers, exporters, distributors and traders.
click here to find a list of Heparin sodium 25,000 units and dextrose 5% in plastic container suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Heparin sodium 25,000 units and dextrose 5% in plastic container DMF (Drug Master File) is a document detailing the whole manufacturing process of Heparin sodium 25,000 units and dextrose 5% in plastic container active pharmaceutical ingredient (API) in detail. Different forms of Heparin sodium 25,000 units and dextrose 5% in plastic container DMFs exist exist since differing nations have different regulations, such as Heparin sodium 25,000 units and dextrose 5% in plastic container USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Heparin sodium 25,000 units and dextrose 5% in plastic container DMF submitted to regulatory agencies in the US is known as a USDMF. Heparin sodium 25,000 units and dextrose 5% in plastic container USDMF includes data on Heparin sodium 25,000 units and dextrose 5% in plastic container's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Heparin sodium 25,000 units and dextrose 5% in plastic container USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Heparin sodium 25,000 units and dextrose 5% in plastic container suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Heparin sodium 25,000 units and dextrose 5% in plastic container Drug Master File in Japan (Heparin sodium 25,000 units and dextrose 5% in plastic container JDMF) empowers Heparin sodium 25,000 units and dextrose 5% in plastic container API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Heparin sodium 25,000 units and dextrose 5% in plastic container JDMF during the approval evaluation for pharmaceutical products. At the time of Heparin sodium 25,000 units and dextrose 5% in plastic container JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Heparin sodium 25,000 units and dextrose 5% in plastic container suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Heparin sodium 25,000 units and dextrose 5% in plastic container Drug Master File in Korea (Heparin sodium 25,000 units and dextrose 5% in plastic container KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Heparin sodium 25,000 units and dextrose 5% in plastic container. The MFDS reviews the Heparin sodium 25,000 units and dextrose 5% in plastic container KDMF as part of the drug registration process and uses the information provided in the Heparin sodium 25,000 units and dextrose 5% in plastic container KDMF to evaluate the safety and efficacy of the drug.
After submitting a Heparin sodium 25,000 units and dextrose 5% in plastic container KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Heparin sodium 25,000 units and dextrose 5% in plastic container API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Heparin sodium 25,000 units and dextrose 5% in plastic container suppliers with KDMF on PharmaCompass.
Heparin sodium 25,000 units and dextrose 5% in plastic container Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Heparin sodium 25,000 units and dextrose 5% in plastic container GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Heparin sodium 25,000 units and dextrose 5% in plastic container GMP manufacturer or Heparin sodium 25,000 units and dextrose 5% in plastic container GMP API supplier for your needs.
A Heparin sodium 25,000 units and dextrose 5% in plastic container CoA (Certificate of Analysis) is a formal document that attests to Heparin sodium 25,000 units and dextrose 5% in plastic container's compliance with Heparin sodium 25,000 units and dextrose 5% in plastic container specifications and serves as a tool for batch-level quality control.
Heparin sodium 25,000 units and dextrose 5% in plastic container CoA mostly includes findings from lab analyses of a specific batch. For each Heparin sodium 25,000 units and dextrose 5% in plastic container CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Heparin sodium 25,000 units and dextrose 5% in plastic container may be tested according to a variety of international standards, such as European Pharmacopoeia (Heparin sodium 25,000 units and dextrose 5% in plastic container EP), Heparin sodium 25,000 units and dextrose 5% in plastic container JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Heparin sodium 25,000 units and dextrose 5% in plastic container USP).